CA Patent

CA3228195A1 — Methods for treatment of non-small cell lung cancer (nsclc)

Assigned to Janssen Biotech Inc · Expires 2025-06-30 · 1y expired

What this patent protects

The present disclosure provides methods for treating EGFR-positive non-small cell lung cancer (NSCLC) in a subject that is treatment naive.

USPTO Abstract

The present disclosure provides methods for treating EGFR-positive non-small cell lung cancer (NSCLC) in a subject that is treatment naive.

Drugs covered by this patent

Patent Metadata

Patent number
CA3228195A1
Jurisdiction
CA
Classification
—
Expires
2025-06-30
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Biotech Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.